Endo receives FDA approval for sterile injectable facility in Indore, India

Endo announced that the U.S. FDA approved commercial production of VASOSTRICT at its new 20,000-square-foot aseptic manufacturing facility in Indore, India. The site increases sterile injectable capacity and is expected to begin production in 2026.

“The U.S. Food and Drug Administration (FDA) has approved commercial production of VASOSTRICT at the company's newest aseptic manufacturing facility in Indore, India.”investor.endo.com

• 1 source
• investor.endo.comEndo Receives U.S. FDA Approval of Manufacturing Facility in Indore, India - Dec 9, 2024Dec 9, 2024

Summarized from public sources; check the original articles before acting on it.